AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2023
Dec 28, 2023
30604_dirs_2023-12-28_fcfcf5d5-1cb8-4f39-a42f-979e438a886d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2023-12-26
Reporting Person: MCCORMICK FRANK (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-12-26 | Common Stock | S | 100000 | $42.06 | Disposed | 627689 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 472376 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person, as Trustee of the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 on June 15, 2023.
F2: Represents the weighted average sale price of the shares sold from $42.00 to $42.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017.